Global Peptic Ulcer Drugs Market Strategic Research Report

Scope of the Report

The global Peptic Ulcer Drugs market size is predicted to grow from US$ 20,020 million in 2025 to US$ 25,760 million in 2032; it is expected to grow at a CAGR of 3.7% from 2026 to 2032.

Peptic ulcer drugs are medications specifically designed to treat and manage peptic ulcers, which are sores that develop on the lining of the stomach, small intestine, or esophagus due to the erosion caused by stomach acid. These drugs work by reducing stomach acid production, protecting the stomach lining, or eradicating the bacteria Helicobacter pylori, which is commonly associated with ulcer formation. The main classes of peptic ulcer drugs include proton pump inhibitors (PPIs), such as omeprazole and esomeprazole, which effectively lower acid secretion by inhibiting the proton pumps in the stomach lining. H2-receptor antagonists, like ranitidine and famotidine, also reduce acid production by blocking histamine receptors on acid-producing cells. Additionally, antacids neutralize existing stomach acid to provide immediate relief from ulcer-related symptoms. Other medications, such as sucralfate, create a protective barrier over the ulcer to aid healing, and antibiotics are used in combination therapies to eradicate H. pylori. These drugs play a crucial role in alleviating symptoms, promoting healing, and preventing ulcer recurrence, significantly improving the quality of life for individuals suffering from peptic ulcers.

The main global Peptic Ulcer Drugs players include Takeda Pharmaceutical, AstraZeneca, Pfizer, Teva Pharmaceuticals, EA Pharma, etc. The top five Peptic Ulcer Drugs players account for approximately 43% of the total market. United States is the largest consumer market for Peptic Ulcer Drugs, accounting for about 30%, followed by Europe and China. In terms of type, Proton Pump Inhibitors is the largest segment, with a share over 68%. And in terms of application, the largest application is Hospital and Clinic, followed by Drugstore.

The market for peptic ulcer drugs is evolving rapidly, driven by advancements in treatment options, increasing prevalence of gastrointestinal disorders, and a growing focus on personalized medicine. Proton pump inhibitors (PPIs) continue to dominate the market due to their efficacy in reducing stomach acid production and promoting ulcer healing. However, there is a notable shift towards exploring alternative therapies and combination treatments to address issues such as antibiotic resistance and long-term PPI use side effects. H2-receptor antagonists remain relevant, especially for patients who experience fewer side effects or need cost-effective solutions.

Recent trends highlight a growing interest in novel drug formulations and over-the-counter (OTC) options, as well as an increased emphasis on targeted therapies that address specific causes of ulcers, such as Helicobacter pylori infection. The market is also seeing innovations in drug delivery systems and adjunctive therapies designed to enhance treatment outcomes and patient compliance. Furthermore, rising awareness and diagnostic advancements are contributing to early detection and management of peptic ulcers, further driving market growth.

This report presents a comprehensive overview of the global Peptic Ulcer Drugs market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Proton Pump Inhibitors
• H2-Antagonists
• Antacids
• Others

Segment by players, this report covers

• AstraZeneca
• Livzon Pharmaceutical
• Jiangsu Aosaikang Pharmaceutical
• CTTQ
• Luoxin Pharmaceuticals
• Takeda
• Eisai
• Jumpcan Pharmaceutical
• Zhejiang Conba Pharmaceutical
• Youcare Pharmaceutical
• Chongqing Lummy Pharmaceutical
• Huadong Medicine
• Hansoh Pharmaceutical
• CR Double-Crane
• Hunan Warrant Pharmaceutical
• Changzhou Siyao Pharmaceuticals
• Chongqing Pharscin Pharmaceutical
• Lionco Pharmaceutical
• Jiangsu Wuzhong Pharmaceutical
• Cisen Pharmaceutical

Segment by Application

• Hospital and Clinic
• Drugstore

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Peptic Ulcer Drugs market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital and Clinic, Drugstore evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact